Skip to content

A randomized, double-blind, placebo-controlled trial evaluating the effect of denosumab in elderly patients with intertrochanteric fracture

A randomized, double-blind, placebo-controlled trial evaluating the effect of denosumab in elderly patients with intertrochanteric fracture

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220620001
Enrollment
86
Registered
2022-06-20
Start date
2022-09-29
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative osteoporotic intertrochanteric fracture in elderly Hip fracture, elderly, denosumab, osteoporosis, functional recovery

Interventions

Denosumab 60mg prepared in 1ml syringe subcutaneously injection single dose,Normal saline solution 1ml prepared in 1ml syringe identical to denosumab group subcutaneously injection single dose
Experimental Drug,Placebo Comparator No treatment
Denosumab,Placebo

Sponsors

Mahidol University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patient age equal or greater than 60 years old 2. Intertrochanteric fracture patient following low energy mechanism of injury and treated by internal fixation either cephalomedullay nail or dynamic hip screw 3. Proximal femoral fracture in trochanteric region defined as 31A by AO classification

Exclusion criteria

Exclusion criteria: 1. Patient who has early postoperative complication within 2 weeks after surgical treatment with internal fixation such as wound infection, iatrogenic fracture 2. Patient who cannot participate in weight bearing rehabilitation program or prohibited by surgeon 3. Multiple fractures 4. Multiple injuries 5. Pathological fracture caused by primary or secondary bone tumor classified as malignancy confirmed by pathology report 6. Contraindication to denosumab such as chronic kidney disease with glomerular filtration rate less than 15 ml/min, drug hypersensitivity, hypocalcemia with serum calcium less than 9.0 mg/dL 7. Recent prescribed medication 6 months prior to fracture with denosumab, parathyroid hormone analogue, and high dose glucocorticoids more than 5mg of prednisolone daily 8. Recent bisphosphonate prescription 1 year prior to fracture or consecutive 2 years within 5 years 9. Cognitive impairment assessed by TMSE less than 25 points

Design outcomes

Primary

MeasureTime frame
Functional outcome 0, 3, 6 months Barthel index

Secondary

MeasureTime frame
Functional outcome 0, 3, 6 months modified Harris Hip Score,Sarcopenia 0, 3, 6 months Hand grip strength,Sarcopenia 0, 3, 6 months Muscle mass by bioelectrical impedance analysis,Sarcopenia 0, 3, 6 months Time Up and Go test,Fracture healing 0, 3, 6 months Union of fracture,Fracture healing 0, 3, 6 months Radiographic Union Score for Hip,Fracture Healing 0, 3, 6 months Loss of reduction, Fixation failure

Countries

Thailand

Contacts

Public ContactEkasame Vanitchareonkul

Siriraj Hospital, Mahidol University

artvanit@gmail.com0896923204

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026